NPI: 1427080415 · SHOREVIEW, MN 55126 · Durable Medical Equipment & Medical Supplies · NPI assigned 07/07/2006
Authorized official BADLANI, SAMEER controls 20+ related entities in our dataset. Read more
| Authorized Official | BADLANI, SAMEER (CHAIRMAN OF THE BOARD) |
| NPI Enumeration Date | 07/07/2006 |
Other providers sharing the same authorized official: BADLANI, SAMEER
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 9,803 | $280K |
| 2019 | 12,318 | $1.15M |
| 2020 | 10,814 | $840K |
| 2021 | 9,742 | $500K |
| 2022 | 12,960 | $375K |
| 2023 | 13,879 | $545K |
| 2024 | 9,072 | $443K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| J2315 | Injection, naltrexone, depot form, 1 mg | 868 | 764 | $991K |
| A9276 | Sensor; invasive (e.g., subcutaneous), disposable, for use with non-durable medical equipment interstitial continuous glucose monitoring system, one unit = 1 day supply | 4,587 | 3,721 | $929K |
| A4230 | Infusion set for external insulin pump, non needle cannula type | 4,293 | 3,690 | $507K |
| K0553 | Supply allowance for therapeutic continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service | 8,058 | 6,656 | $348K |
| A9277 | Transmitter; external, for use with non-durable medical equipment interstitial continuous glucose monitoring system | 2,061 | 1,541 | $329K |
| A4239 | Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service | 6,451 | 6,113 | $314K |
| A9274 | External ambulatory insulin delivery system, disposable, each, includes all supplies and accessories | 414 | 375 | $204K |
| A4232 | Syringe with needle for external insulin pump, sterile, 3 cc | 2,970 | 2,525 | $105K |
| J7518 | Mycophenolic acid, oral, 180 mg | 2,304 | 2,070 | $95K |
| J7507 | Tacrolimus, immediate release, oral, 1 mg | 9,056 | 6,408 | $74K |
| A9278 | Receiver (monitor); external, for use with non-durable medical equipment interstitial continuous glucose monitoring system | 256 | 240 | $57K |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | 11,601 | 10,491 | $35K |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | 13,383 | 9,259 | $31K |
| A4225 | Supplies for external insulin infusion pump, syringe type cartridge, sterile, each | 1,432 | 1,295 | $30K |
| J7517 | Mycophenolate mofetil, oral, 250 mg | 5,984 | 5,349 | $28K |
| A4224 | Supplies for maintenance of insulin infusion catheter, per week | 209 | 193 | $20K |
| J7515 | Cyclosporine, oral, 25 mg | 619 | 577 | $10K |
| K0554 | Receiver (monitor), dedicated, for use with therapeutic glucose continuous monitor system | 100 | 97 | $10K |
| E2103 | Non-adjunctive, non-implanted continuous glucose monitor or receiver | 163 | 161 | $8K |
| J7639 | Dornase alfa, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 13 | 13 | $7K |
| Q0513 | Pharmacy dispensing fee for inhalation drug(s); per 30 days | 374 | 352 | $2K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 3,313 | 2,910 | $229.88 |
| A4253 | Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips | 16 | 13 | $89.88 |
| Q0510 | Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant | 33 | 32 | $40.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 30 | 27 | $34.29 |